331.10
+0.30
+(0.09%)
At close: January 10 at 8:20:01 AM GMT+1
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 8 | 11 | 11 |
| Avg. Estimate | 866.33M | 525.37M | 2.53B | 2.75B |
| Low Estimate | 830M | 495.9M | 2.46B | 2.53B |
| High Estimate | 901.6M | 572.1M | 2.56B | 2.83B |
| Year Ago Sales | 805.11M | 466.61M | 2.27B | 2.53B |
| Sales Growth (year/est) | 7.60% | 12.59% | 11.29% | 8.70% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| AKX.F | -- | -- | -- | -- |
| S&P 500 | 8.59% | 11.42% | 13.98% | 13.43% |
Upgrades & Downgrades
| Maintains | Baird: Outperform to Outperform | 11/7/2024 |
| Maintains | Rosenblatt: Neutral to Neutral | 8/6/2024 |
| Initiated | Keybanc: Sector Weight | 6/27/2024 |
| Maintains | Rosenblatt: Neutral to Neutral | 5/3/2024 |
| Reiterates | Rosenblatt: Neutral to Neutral | 3/5/2024 |
| Maintains | Barclays: Underweight to Underweight | 2/22/2024 |